Fish Protein Supplementation and Sarcopenia Outcomes in the Community

NCT ID: NCT05356559

Last Updated: 2022-05-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-25

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sarcopenia is a progressive and generalised skeletal muscle disorder involving the accelerated loss of muscle mass and function that is associated with increase adverse outcomes including falls, functional decline, frailty and mortality. Diet, specifically protein has been proposed to have a role in the prevention and treatment of muscle loss in the older adult population nevertheless there is paucity of research on the effect of protein supplementation on lean body mass and other clinical outcomes in older adults.

This 2-arm parallel, double-blind, randomised, controlled dietary supplement human intervention study aims to investigate the effect of consuming 12.5g (twice daily) Blue Whiting Protein Hydrolysates daily in combination with exercise for 8 weeks on whole body lean mass tissue and measures of muscle strength and functionality in free living community dwelling older adults.

Participants (N150; 75/site (Ulster \& Limerick); 75/group; 50-70 years) will be stratified by age, gender and BMI and randomly allocated to consume two sachets of either the Blue Whiting Protein Hydrolysates powder daily (12.5g at breakfast and lunch (Total 25g)), (mixed with an everyday food / drink product (provided by Ulster University) or an isocalorific maltodextrin citrus flavoured powder (Control) (mixed with an everyday food / drink product).

Assessments to be undertaken pre and post intervention include; body composition including lean tissue mass measured by DXA whole body scan (Ulster site only), Bio-Electrical Impedance Analysis (BIA), hand grip strength, a 'timed get up and go' test, 6 minute walk test, gait speed test, chair stand test, blood pressure measurements, a quality of life questionnaire, a health and lifestyle questionnaire and a physical activity questionnaire. A trained phlebotomist will obtain a 40ml max blood sample from each participant pre and post intervention. Blood samples will be used to measure markers associated with sarcopenia (serum 25(OH)D, pro inflammatory cytokine profile, full lipid profiles and kidney and liver profiles). A 4-day food diary will be collected at baseline only to determine habitual protein intake. At post intervention only, bone mineral density at the spine and hip will be measured by a DXA scanner.

Comparisons will be made (ANCOVA) between the intervention group and control group over time.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Parallel randomised control trial.
Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
Double-blinded

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fish protein

Group Type ACTIVE_COMPARATOR

Intervention

Intervention Type DIETARY_SUPPLEMENT

12.5g (twice daily) Blue Whiting Protein Hydrolysates daily for 8 weeks

Control

Group Type PLACEBO_COMPARATOR

Control

Intervention Type OTHER

Isocalorific Maltodextrin Citrus Flavoured Powder for 8 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intervention

12.5g (twice daily) Blue Whiting Protein Hydrolysates daily for 8 weeks

Intervention Type DIETARY_SUPPLEMENT

Control

Isocalorific Maltodextrin Citrus Flavoured Powder for 8 weeks

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Free-living, apparently healthy older adults
* Able to fast from 10pm prior to the appointment
* Aged 50-70 years at recruitment
* Not regularly taking protein supplements
* Free from serious musculoskeletal injury

Exclusion Criteria

* Adults \<50 years at recruitment
* Food allergy or intolerance that would prevent consumption of fish
* Diagnosed with any form of terminal disease or past medical history of conditions or medications that may interfere with supplementation and/or study outcomes, such as diabetes, kidney, digestive, thyroidal disease
* Cognitive impairment
* Exclusively receiving enteral or parenteral nutrition
* Currently taking any protein supplement
* Undertaking resistance exercise regularly
* Planning to lose weight/go on a special diet
* Any conditions/anomalies that could potentially interfere with the DXA
* Been advised not to undertake physical activity
Minimum Eligible Age

50 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Limerick

OTHER

Sponsor Role collaborator

Bio-Marine Ingredients Ireland

UNKNOWN

Sponsor Role collaborator

University of Ulster

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Human Intervention Studies Unit, Ulster University / Physical Education and Sport Sciences,

Coleraine / Limerick, Co.Londonderry / Ireland, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Philip J Allsopp

Role: CONTACT

+44 28 7012 3125

Mary M Slevin

Role: CONTACT

+44 08 7012 3041

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ruth K Price

Role: primary

+442870123878

Julie J Sittlington

Role: backup

+442870124101

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

21/EM/0140

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

C-Protein in Fatigue and Aging
NCT05926219 RECRUITING NA
Nutrition and Exercise for Sarcopenia
NCT00872911 COMPLETED PHASE1